Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ge, R.; Rajeev, V.; Subramanian, G.; Reiss, K.A.; Liu, D.; Higgins, L.; Joly, A.; Dugar, S.; Chakravarty, J.; Henson, M.; McEnroe, G.; Schreiner, G.; Reiss, M.: Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling. Biochem. Pharmacol., 68, 41–50 (2004)
Ottesen, J.J.; Huse, M.; Sekedat, M.D.; Muir, T.W.: Semisynthesis of phosphovariants of Smad2 reveals a substrate preference of the activated TβRI kinase. Biochemistry, 43, 5698–5706 (2004)
Peng, S.B.; Yan, L.; Xia, X.; Watkins, S.A.; Brooks, H.B.; Beight, D.; Herron, D.K.; Jones, M.L.; Lampe, J.W.; McMillen, W.T.; Mort, N.; Sawyer, J.S.; Yingling, J.M.: Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry, 44, 2293–2304 (2005)
Roberts, H.J.; Hu, S.; Qiu, Q.; Leung, P.C.; Caniggia, I.; Gruslin, A.; Tsang, B.; Peng, C.: Identification of novel isoforms of activin receptor-like kinase 7 (ALK7) generated by alternative splicing and expression of ALK7 and its ligand, Nodal, in human placenta. Biol. Reprod., 68, 1719–1726 (2003)
Sawyer, J.S.; Beight, D.W.; Britt, K.S.; Anderson, B.D.; Campbell, R.M.; Goodson, T., Jr; Herron, D.K.; Li, H.Y.; McMillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Wagner, J.R.; Yan, L.; Zhang, F.; Yingling, J.M.: Synthesis and activity of new aryl-and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg. Med. Chem. Lett., 14, 3581–3584 (2004)
Desgrosellier, J.S.; Mundell, N.A.; McDonnell, M.A.; Moses, H.L.; Barnett, J.V.: Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev. Biol., 280, 201–210 (2005)
Zhang, N.; Kumar, M.; Xu, G.; Ju, W.; Yoon, T.; Xu, E.; Huang, X.; Gaisano, H.; Peng, C.; Wang, Q.: Activin receptor-like kinase 7 induces apoptosis of pancreatic β cells and β cell lines. Diabetologia, 49, 506–518 (2006)
Liu, C.; Gaca, M.D.; Swenson, E.S.; Vellucci, V.F.; Reiss, M.; Wells, R.G.: Smads 2 and 3 are differentially activated by transforming growth factor-β (TGF-β) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-β-independent. J. Biol. Chem., 278, 11721–11728 (2003)
Harrison, C.A.; Gray, P.C.; Koerber, S.C.; Fischer, W.; Vale, W.: Identification of a functional binding site for activin on the type I receptor ALK4. J. Biol. Chem., 278, 21129–21135 (2003)
Kim, B.C.; van Gelder, H.; Kim, T.A.; Lee, H.J.; Baik, K.G.; Chun, H.H.; Lee, D.A.; Choi, K.S.; Kim, S.J.: Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells. J. Biol. Chem., 279, 28458–28465 (2004)
Yakymovych, I.; Heldin, C.H.; Souchelnytskyi, S.: Smad2 phosphorylation by type I receptor. Contribution of arginine 462 and cysteine 463 In the C terminus of Smad2 for specificity. J. Biol. Chem., 279, 35781–35787 (2004)
Ungefroren, H.; Groth, S.; Ruhnke, M.; Kalthoff, H.; Fandrich, F.: Transforming growth factor-β (TGF-β) type I receptor/ALK5-dependent activation of the GADD45β gene mediates the induction of biglycan expression by TGF-β. J. Biol. Chem., 280, 2644–2652 (2005)
Lux, A.; Beil, C.; Majety, M.; Barron, S.; Gallione, C.J.; Kuhn, H.M.; Berg, J.N.; Kioschis, P.; Marchuk, D.A.; Hafner, M.: Human retroviral gag-and gag-pol-like proteins interact with the transforming growth factor-β receptor activin receptor-like kinase 1. J. Biol. Chem., 280, 8482–8493 (2005)
Forrester, S.G.; Warfel, P.W.; Pearce, E.J.: Tegumental expression of a novel type II receptor serine/threonine kinase (SmRK2) in Schistosoma mansoni. Mol. Biochem. Parasitol., 136, 149–156 (2004)
Goumans, M.J.; Valdimarsdottir, G.; Itoh, S.; Lebrin, F.; Larsson, J.; Mummery, C.; Karlsson, S.; ten Dijke, P.: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell, 12, 817–828 (2003)
Mazerbourg, S.; Klein, C.; Roh, J.; Kaivo-Oja, N.; Mottershead, D.G.; Korchynskyi, O.; Ritvos, O.; Hsueh, A.J.: Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5. Mol. Endocrinol., 18, 653–665 (2004)
Halder, S.K.; Beauchamp, R.D.; Datta, P.K.: A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia, 7, 509–521 (2005)
Fink, S.P.; Mikkola, D.; Willson, J.K.V.; Markowitz, S.: TGF-β-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene, 22, 1317–1323 (2003)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2009). Receptor protein serine/threonine kinase. In: Schomburg, D., Schomburg, I., Chang, A. (eds) Springer Handbook of Enzymes. Springer Handbook of Enzymes, vol S4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85701-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-85701-3_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85700-6
Online ISBN: 978-3-540-85701-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)